Search

Displaying results 5841 - 5850 of 6198 in total
  1. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  2. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).

  3. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.

  4. Drug

    Disoxaril

    go.drugbank.com/drugs/DB08726
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring.

  5. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel. … Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  6. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).

  7. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structu...

  8. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

  9. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with

  10. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).